Cargando…
Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
BACKGROUND/AIM: This retrospective study assessed the efficacy, safety, and the predictors of sustained viral response (SVR) to a 48-week-course of peginterferon α-2a (Pegasys) and ribavirin combination therapy in 335 consecutive Saudi patients with chronic hepatitis C virus (HCV) infection. MATERIA...
Autores principales: | Al Ashgar, Hamad, Khan, Mohammed Q., Helmy, Ahmed, Al Swat, Khalid, Al Shehri, Abdullah, Al Kalbani, Abdalla, Peedikayel, Musthafa, Al Kahtani, Khalid, Al Quaiz, Mohammed, Rezeig, Mohammed, Kagevi, Ingvar, Al Fadda, Mohammed |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702904/ https://www.ncbi.nlm.nih.gov/pubmed/19568501 http://dx.doi.org/10.4103/1319-3767.39619 |
Ejemplares similares
-
Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4
por: Al Ashgar, Hamad, et al.
Publicado: (2009) -
Inflammatory bowel disease in Saudi Arabia: a hospital-based clinical study of 312 patients
por: Al Fadda, Mohammed, et al.
Publicado: (2012) -
Wilson disease in 71 patients followed for over two decades in a tertiary center in Saudi Arabia: a retrospective review
por: Al Fadda, Mohammed, et al.
Publicado: (2012) -
Prospective Trial in Saudi Arabia Comparing the 14-day Standard Triple Therapy with the 10-day Sequential Therapy for Treatment of Helicobacter Pylori Infection
por: Alsohaibani, Fahad, et al.
Publicado: (2015) -
HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)